Personalis (NASDAQ:PSNL – Get Free Report) issued its earnings results on Wednesday. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.06), FiscalAI reports. The business had revenue of $25.60 million during the quarter, compared to analyst estimates of $21.54 million. Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%.
Personalis Stock Up 0.3%
Shares of PSNL traded up $0.04 during midday trading on Wednesday, reaching $15.79. 2,217,743 shares of the stock were exchanged, compared to its average volume of 2,610,416. Personalis has a 12-month low of $4.95 and a 12-month high of $18.89. The firm has a 50 day simple moving average of $16.26 and a 200-day simple moving average of $11.39. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -14.49 and a beta of 2.40.
Insider Transactions at Personalis
In related news, SVP Stephen Moore sold 2,068 shares of the stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $16.22, for a total value of $33,542.96. Following the transaction, the senior vice president owned 90,257 shares in the company, valued at approximately $1,463,968.54. This represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Christopher M. Hall sold 7,459 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $16.22, for a total transaction of $120,984.98. Following the transaction, the chief executive officer directly owned 228,527 shares in the company, valued at approximately $3,706,707.94. The trade was a 3.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 16,456 shares of company stock valued at $266,916 in the last quarter. Corporate insiders own 4.20% of the company’s stock.
Analysts Set New Price Targets
A number of brokerages recently commented on PSNL. Craig Hallum downgraded shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 price objective on the stock. in a research report on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research note on Thursday, October 15th. UBS Group downgraded shares of Personalis from a “buy” rating to a “neutral” rating in a research report on Tuesday, October 6th. BTIG Research lowered shares of Personalis from a “buy” rating to a “neutral” rating in a research note on Tuesday, October 6th. Finally, Morgan Stanley lifted their target price on shares of Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Three equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $14.54.
Get Our Latest Stock Analysis on Personalis
Personalis Company Profile
Personalis, Inc is a genomics company focused on applying advanced sequencing and bioinformatics to cancer research and precision medicine. The company develops tests and data platforms designed to help researchers and clinicians characterize tumors, monitor disease, and support the development of targeted therapies.
Its product portfolio includes the NeXT Platform, which analyzes tumor and normal DNA and RNA to provide a detailed view of cancer biology, as well as products such as NeXT Dx, NeXT Liquid Biopsy, and NeXT Personal.
Read More
- Five stocks we like better than Personalis
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.
